CVKD

Cadrenal Therapeutics, Inc.

0.53 USD

Last updated Dec 10, 20:15 UTC

Yesterday HIGH

$0.56

Yesterday LOW

$0.47

52w HIGH

$6.75

52w LOW

$0.4

EPS

-0.07

PE

-7.52

Next Earnings

Sep 19, 2023

Overview News Government Trades

Cadrenal Therapeutics, Inc. stock is up 25.26% since 30 days ago. The next earnings date is Sep 19, 2023. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 1 December’s closed higher than November. 100% of analysts rate it a buy.

We are focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib. Our principal executive offices are located at 822 A1A North, Suite 306, Ponte Vedra, Florida.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

www.cadrenal.com

Lisa Levin

Wed Jul 12, 2023

Why Lucid Group Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Gainers Healthcare Triangle, Inc. (NASDAQ: HCTI) shares climbed 171.2% to $8.84 as the company launched initiative to prevent ransomware attacks in the $35 billion healthcare data market.
Benzinga Insights

Wed Jul 12, 2023

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Lisa Levin

Wed Jul 12, 2023

Why ImmuCell Are Trading Higher; Here Are 20 Stocks Moving Premarket

Gainers Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) shares surged 131.6% to $4.03 in pre-market trading after gaining 15% on Tuesday.
Benzinga Insights

Fri Jul 7, 2023

12 Health Care Stocks Moving In Friday's Pre-Market Session
AJ Fabino

Fri Jun 16, 2023

Cava Stock Makes A Stand In Mixed IPO Landscape: Where Does It Rank Against Other 2023 Wall Street Debuts?

In a year that’s seen a sharp decline in initial public offerings, Washington, D.C.-based Mediterranean restaurant chain Cava Group (NYSE: CAVA) made a striking first public appearance on the New York Stock Exchange on Thursday, with shares opening at $42,
Benzinga Insights

Mon May 15, 2023

12 Health Care Stocks Moving In Monday's Pre-Market Session
Happy Mohamed

Wed May 10, 2023

Cadrenal Therapeutics Provides Q1 2023 Corporate Update

Cadrenal Therapeutics, Inc., (NASDAQ:CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today provided a
Benzinga Insights

Fri Apr 21, 2023

12 Health Care Stocks Moving In Friday's Intraday Session
Happy Mohamed

Thu Mar 30, 2023

Cadrenal Therapeutics Provides FY22 Corporate Update

Cadrenal Therapeutics, Inc., (NASDAQ:CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today provided a
Lisa Levin

Thu Mar 23, 2023

MAIA Biotechnology And 2 Other Stocks Under $5 Insiders Are Aggressively Buying

The Dow Jones closed lower by more than 500 points on Wednesday following Fed’s rate decision. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.